Q: With the FDA black box warning, are SSRIs still considered first-line treatment for children and adolescents?
A: Yes. Current evidence and clinical practice guidelines continue to support selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacologic treatment for pediatric anxiety disorders and for moderate to severe depression when medication is clinically indicated. The Canadian Academy of Child and Adolescent Psychiatry, recent pediatric prescribing reviews, and current evidence-based treatment reviews all continue to recommend SSRIs (particularly fluoxetine and escitalopram for depression) as first-line medications when combined with appropriate monitoring.¹⁻³
The black box warning did not conclude that antidepressants cause suicide. Rather, it highlighted a small increase in treatment-emergent suicidal thoughts and behaviors observed during clinical trials, emphasizing the importance of careful monitoring during the first weeks of treatment.⁴
Q: Should the suicide warning make me avoid prescribing SSRIs altogether?
A: No. The available evidence suggests that avoiding effective treatment carries its own risks. Depression and anxiety themselves are among the strongest risk factors for suicidal ideation and suicide attempts in youth. Untreated illness is associated with impaired functioning, substance use, self-harm, and suicide.² ³
Clinical trials found an increase in suicidal thoughts and behaviors, but no completed suicides occurred in the pediatric antidepressant trials that informed the FDA warning.⁴ ⁵ At the same time, antidepressants consistently improve symptoms for many children and adolescents, particularly when combined with psychotherapy.² ⁵ The goal is not to avoid treatment; it is to prescribe thoughtfully, educate families, and monitor closely.
Q: How large is the increased risk?
A: Across pediatric antidepressant trials, suicidal thoughts or behaviors occurred in approximately 4% of youth receiving antidepressants compared with about 2% receiving placebo. This represents an absolute increase of roughly two additional cases per 100 treated patients.⁴
Importantly: No completed suicides occurred in these studies.⁴ ⁵ Most events involved suicidal thoughts rather than suicide attempts.⁴ The greatest risk appears during the first several weeks after starting treatment or increasing the dose.² ³
This is why early follow-up and family education are essential components of treatment.
Q: Which medication has the strongest evidence?
A: Fluoxetine has the most consistent evidence supporting its effectiveness in pediatric major depressive disorder and remains the best-supported first-line antidepressant for depression in children and adolescents.¹ ² ⁶
Other SSRIs, escitalopram, also have evidence supporting their use for specific indications, particularly anxiety disorders and adolescent depression.¹ ²
Current evidence does not support viewing all antidepressants as equally effective in youth. The 2016 Lancet network meta-analysis found that fluoxetine was the only antidepressant consistently demonstrating superiority over placebo for pediatric major depressive disorder, while several SNRIs (venlafaxine and duloxetine) showed poorer tolerability or higher rates of treatment discontinuation due to adverse events.⁶
Q: I've heard antidepressants increase suicide rates nationally. Is that true?
A: The evidence does not support that conclusion. Several population-level studies have found that regions with higher rates of antidepressant prescribing had lower adolescent suicide rates, although these ecological studies cannot establish causation.⁷
Following the FDA warning, antidepressant prescribing declined substantially among children and adolescents. Subsequent observational studies raised concerns that reduced prescribing may have coincided with increases in youth suicide rates, prompting renewed discussion regarding the unintended consequences of the warning.⁸
While many factors influence suicide rates, current evidence suggests that appropriately treating depression remains an important component of suicide prevention.¹ ² ⁸
Q: What is the bottom line for prescribers?
A: The evidence today is stronger than it was when the FDA issued the black box warning in 2004. SSRIs remain first-line pharmacologic treatment for pediatric anxiety disorders and an evidence-based option for moderate to severe depression when medication is indicated.¹⁻³ ⁶ The small increase in treatment-emergent suicidal thoughts must be taken seriously, but it should be weighed against the substantial risks of untreated psychiatric illness.² ⁵
The safest approach is not to avoid antidepressants; it is to prescribe them carefully, educate families, partner with psychotherapy whenever possible, and provide close follow-up during the early phases of treatment.¹⁻³
